Treatment for Non-suicidal Self-injury using Stanford Neuromodulation Therapy
Stanford Neuromodulation Therapy (SNT) for Non-suicidal Self-injury (NSSI)
This study is testing if Stanford Neuromodulation Therapy can help teenagers who struggle with non-suicidal self-injury feel better compared to another treatment called rTMS.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 12 Years to 18 Years |
| Sex | All |
| Sponsor | Anhui Medical University Academic / other |
| Locations | 1 site (Hefei) |
| Trial ID | NCT06139484 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of Stanford Neuromodulation Therapy (SNT) on patients with Non-suicidal Self-injury (NSSI). A total of 80 patients aged 12-18 diagnosed with NSSI were randomized into two groups: one receiving SNT and the other receiving repetitive Transcranial Magnetic Stimulation (rTMS). The treatment involves daily sessions over five consecutive days, with assessments conducted before and after the intervention to evaluate efficacy and underlying neural mechanisms. The study utilizes neuropsychological tests and MRI scans to gather comprehensive data on treatment effects.
Who should consider this trial
Good fit: Ideal candidates are adolescents aged 12-18 who have been diagnosed with NSSI and have exhibited self-injurious behaviors in the past six months.
Not a fit: Patients with suicidal ideation or those who have a history of neurological disorders or substance abuse may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce self-injurious behaviors in adolescents with NSSI.
How similar studies have performed: While the approach is innovative, similar studies using Transcranial Magnetic Stimulation have shown promise in treating various psychiatric conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * the patients were diagnosed by 2 or more senior clinical psychiatrists, meeting DSM-V criteria, and having 1 or more non-suicidal self-injurious behaviors in the last 6 months * 12-18 years of age * The medicine has not changed in the 4 weeks prior to or after this study, and if it has to be changed, the treatment medication is required to be at a subtherapeutic dosage level Exclusion Criteria: * the patients has suicidal ideation, or have committed suicidal behavior * T1 or T2 weighted phase magnetic resonance images show focal brain lesions * patients had neurological disorders such as epilepsy, or serious physical illnesses * patients had history of substance abuse and drug dependence in the last 6 months or use of anticonvulsant drugs in the last 3 months * patiens had received radial cranial electrical stimulation or magnetic stimulation treatment in the last 3 months, or received electroconvulsive therapy in the last 6 months * patients had previous significant head trauma or with EEG abnormality in the last 1 month * body-mounted devices unsuitable for treatment, such as pacemakers, artificial valves and other metal implants.
Where this trial is running
Hefei
- Anhui Medical University — Hefei, China (Recruiting)
Study contacts
- Study coordinator: Kai Wang, PhD
- Email: wangkai1964@126.com
- Phone: +86-0551-62923704
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.